|
|
Neuronetics Inc (NASDAQ: STIM) |
|
Price: $2.8400
$-0.10 
-3.401%
|
| Day's High:
| $2.9600000381469727
| Week Perf:
| -4.7 %
|
| Day's Low: |
$ 2.76 |
30 Day Perf: |
43.43 % |
| Volume (M): |
963,629 |
52 Wk High: |
$ 3.71 |
| Volume (M$): |
$ 0 |
52 Wk Avg: |
$1.93 |
| Open: |
$2.93 |
52 Wk Low: |
$0.80 |
|
|
| Market Capitalization (Millions $) |
198 |
| Shares
Outstanding (Millions) |
70 |
| Employees |
658 |
| Revenues (TTM) (Millions $) |
151 |
| Net Income (TTM) (Millions $) |
-37 |
| Cash Flow (TTM) (Millions $) |
-2 |
| Capital Exp. (TTM) (Millions $) |
1 |
Business Description
Neuronetics Inc is a medical technology company that focuses on developing and commercializing non-invasive brain stimulation therapies for patients with psychiatric and neurological disorders. The company's flagship product is NeuroStar Advanced Therapy, which utilizes transcranial magnetic stimulation (TMS) to target specific areas of the brain involved in mood regulation.
NeuroStar Advanced Therapy is FDA-approved for the treatment of major depressive disorder (MDD) and is backed by clinical studies demonstrating its effectiveness. The procedure involves the use of a non-invasive device that delivers magnetic pulses to the brain, stimulating the nerve cells involved in mood regulation.
Neuronetics Inc is committed to providing alternative treatment options for patients who have not responded well to traditional therapies, such as medication or talk therapy. They aim to improve patients' quality of life by reducing symptoms of depression and other psychiatric disorders.
The company is based in Malvern, Pennsylvania, and collaborates with healthcare professionals, researchers, and patients to advance the understanding and adoption of TMS therapy. Neuronetics Inc is dedicated to ongoing research and development to expand the applications of TMS technology and improve patient outcomes in the field of mental health.
Company Address: 3222 Phoenixville Pike Malvern 19355 PA
Company Phone Number: 600-7555 Stock Exchange / Ticker: NASDAQ STIM
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Shares
Published Mon, Mar 3 2025 9:30 PM UTC
Neuronetics Enhances Team with Inducement Grants Amid Strategic Growth InitiativesNeuronetics, Inc. (NASDAQ: STIM), a prominent player in the medical technology landscape, has recently announced an inducement grant in accordance with NASDAQ Listing Rule 5635(c)(4). As of March 3, 2025, the company bestowed Restricted Stock Units (RSUs), comprising a total of 24,750 shares of...
|
| Shares
Published Thu, Feb 6 2025 9:24 PM UTC
In a strategic move aimed at bolstering its financial position, Neuronetics, Inc. (NASDAQ: STIM) has announced an underwritten public offering of its common stock, a decision that was made public on February 6, 2025. The Company is not only looking to raise capital through this offering but has also indicated that it may grant the underwriters a 30-day option to purchase an...
|
| Stock Market Announcement
Published Wed, Dec 18 2024 9:30 PM UTC
Neuronetics Strengthens Workforce with Inducement Grants Under NASDAQ Rule 5635(c)(4) A Strategic Move to Enhance Talent Acquisition Malvern, PA, December 18, 2024 Neuronetics, Inc. (NASDAQ: STIM), a pioneering commercial-stage medical technology company dedicated to improving the lives of individuals affected by neurohealth disorders, has made noteworthy announcements re...
|
| Contract
Published Tue, Dec 10 2024 3:01 PM UTC
In a significant development for the mental health industry, Neuronetics, Inc. (NASDAQ: STIM) and Greenbrook TMS Inc. (OTCMKTS: GBNHF) have announced the successful completion of a strategic acquisition that promises to reshape therapeutic options for patients battling depression and other mental health disorders. The transaction, officially concluded on December 10, 2024, m...
|
| Product Service News
Published Wed, Sep 25 2024 12:31 PM UTC
Health Care Service Corporation Expands TMS Coverage for Adolescents: A Ray of Hope in Mental Health Amid Challenging ROI for Neuronetics Inc. In a landmark decision that aims to expand access to innovative mental health treatments, Health Care Service Corporation (HCSC), the largest customer-owned health insurer in the United States, has announced an updated policy that inc...
|
Fundamental Analysis
| Per Share |
Current |
| Earnings (TTM) |
-0.55 $ |
| Revenues (TTM) |
2.17 $
|
| Cash Flow (TTM) |
- |
| Cash |
0.27 $
|
| Book Value |
0.25 $
|
| Dividend (TTM) |
0 $ |
| Efficiency
|
Current |
| Revenue per Employee
(TTM) |
229,064 |
| Net
Income per Employee (TTM) |
-56,574 |
| Receivable Turnover Ratio (TTM) |
7.82 |
| Inventory Turnover Ratio (TTM) |
17.04 |
| Asset Turnover Ratio (TTM) |
1.1 |
|
|
| Per Share |
|
| Earnings (TTM) |
-0.55 $
|
| Revenues (TTM) |
2.17 $ |
| Cash Flow (TTM) |
- |
| Cash |
0.27 $
|
| Book Value |
0.25 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
| Service |
|
 63.04 % |
of total Revenue |
| Product Category U S |
|
100.21 % |
of total Revenue |
| Product Category U S Revenues NeuroStar Advanced Therapy System |
|
9.38 % |
of total Revenue |
| Product Category U S Revenues Treatment sessions |
|
26.71 % |
of total Revenue |
| Product Category U S Revenues Clinic revenue |
|
63.04 % |
of total Revenue |
| Product Category U S Revenues Other |
|
1.09 % |
of total Revenue |
| Product Category International |
|
0.67 % |
of total Revenue |
| Product Category International Revenues NeuroStar Advanced Therapy System |
|
0.13 % |
of total Revenue |
| Product Category International Revenues Treatment sessions |
|
0.36 % |
of total Revenue |
| Product Category International Revenues Other |
|
0.17 % |
of total Revenue |
| segment |
|
100.88 % |
of total Revenue |
| Med Device segment |
|
37.84 % |
of total Revenue |
| Clinic Service segment |
|
63.04 % |
of total Revenue |
| |
On November 12 2024 the Neuronetics Inc provided following guidance
nnNeuronetics Inc. Reports Impressive Financial and Operational Performance in Third Quarter 2024nn
nnMALVERN, Pa., November 12, 2024nn – In a recently issued press release concerning its third-quarter results, Neuronetics, Inc. (NASDAQ: STIM) disclosed substantial advancements in both its financial and operational metrics. Importantly, the company’s updated financial guidance indicates that it anticipates reaching cash flow breakeven by the third quarter of 2025.
It is key to note a correction from the earlier announcement regarding the expectations set forth for achieving cash flow breakeven. Specifically, in the section discussing the stockholders' approval for the acquisition of Gre...
|
|
|
10.82%